Business:
Optogenetics
Drug notes:
ML-007 Clin1 dyskinesias. Clin1 schizophrenia; ML-016 RD/Clin0 depression; ML-009 RD/Clin0 hyperactivity/impulsivity; ML-105 RD depression
About:
MapLight Therapeutics is developing novel therapeutics for patients with disorders of the central nervous system. Given the complexity of the brain, diseases with highly specific symptoms should be treated with the same therapeutics. MapLight is using the combination of transcriptomics, optogenetics and STARmap to develop a strong pipeline of safe, effective therapeutics. Optogenetics is used to identify key cell types, transcriptomics is to find targets and STARmap is used to visualize neural circuits. MapLight has already brought two novel therapeutics to the clinic, with more on the horizon.
TMF Specialist Burlington, MA|8 days ago
Clinical Data Manager Burlington, MA|8 days ago
Senior Director, Clinical Development Burlington, MA|21 days ago
Executive Director, Medical Writing United States|22 days ago
Associate Director, Corporate Strategy Redwood City, CA|28 days ago
Senior Clinical Research Associate (CRA) Raleigh-Durham-Chapel Hill Area|29 days ago
Senior Manager, Clinical Sourcing and Contract Man... Burlington, MA|43 days ago
Director, Clinical Pharmacology & Pharmacometrics Burlington, MA|44 days ago
Senior Director, CMC Program Management Burlington, MA|57 days ago
Senior Clinical Trial Manager United States|59 days ago
Clinical Scientist, Clinical Development Burlington, MA|64 days ago
VP, Chemistry Manufacturing and Controls (CMC) Burlington, MA|69 days ago
Director, Regulatory CMC Burlington, MA|83 days ago
Scientist, Molecular Pharmacology Redwood City, CA|Posting date unknown
Senior Scientist, Analytical Development - Drug Su... Burlington, MA|Posting date unknown
Medicinal Chemist Burlington, MA|Posting date unknown
Senior Director, Quality Assurance Burlington, MA|Posting date unknown